This page has moved! Click here to view the most up-to-date version of this page on the White Rose Wiki.
Dewpoint Therapeutics is an American biotechnology company based in Boston, Massachusetts.
Dewpoint participated as an industry partner in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership hosted by the Foundation for the National Institutes of Health.[1]
Name | Position | Notes |
---|---|---|
Kara Carter | Senior Vice President, Discovery Biology | ACTIV Preclinical and TRACE Working Groups |
Investors in Dewpoint Therapeutics include:[2][3][4]
Dewpoint is developing products through partnerships with:[7]
ACTIV. National Institutes of Health (NIH). Retrieved April 1, 2022, from http://archive.today/2022.01.11-042823/https://www.nih.gov/research-training/medical-research-initiatives/activ ↩︎
Series A - Dewpoint Therapeutics - 2019-01-30 - Crunchbase Funding Round Profile. Crunchbase. Retrieved July 3, 2023, from https://www.crunchbase.com/funding_round/dewpoint-therapeutics-series-a--aac46ca0 ↩︎
Series B - Dewpoint Therapeutics - 2020-09-29 - Crunchbase Funding Round Profile. Crunchbase. Retrieved July 3, 2023, from https://www.crunchbase.com/funding_round/dewpoint-therapeutics-series-b--80fadead ↩︎
Bressi, J., & Peterson, S. (2022, February 3). Dewpoint Therapeutics Announces Completion of $150 Million Series C Financing. Dewpoint Therapeutics. https://web.archive.org/web/20230703183902/https://dewpointx.com/dewpoint-therapeutics-announces-completion-of-150-million-series-c-financing/ ↩︎
All Companies. (2022, October 28). General Catalyst. http://archive.today/2022.12.03-033447/https://www.generalcatalyst.com/list ↩︎
Portfolio. SoftBank Vision Fund. Retrieved May 5, 2023, from https://web.archive.org/web/20230505171511/https://visionfund.com/portfolio ↩︎
Pipeline. Dewpoint Therapeutics. Retrieved July 3, 2023, from http://archive.today/2023.07.03-184111/https://dewpointx.com/pipeline/%23partnerships ↩︎